#China #Shanghai #Frost & Sullivan #WuXi Biologics #CRDMO Industry

WuXi Biologics Honored with 2025 Global Customer Value Leadership Recognition

WuXi Biologics, a standout Contract Research, Development, and Manufacturing Organization (CRDMO), proudly announced its recent accolade from Frost & Sullivan: the 2025 Global Customer Value Leadership Recognition. This distinction underscores the company’s unwavering commitment to delivering outstanding value to its customers through advanced technology, operational efficiency, and a keen understanding of client needs in the rapidly evolving biopharmaceutical landscape.

A Commitment to Excellence

Frost & Sullivan’s recognition of WuXi Biologics highlights the organization’s comprehensive CRDMO platform. This integrated approach facilitates smoother transitions from early-stage discovery to final-stage manufacturing and commercialization. Such a streamlined strategy not only mitigates complexities and costs but also speeds up timelines, positioning WuXi Biologics as a reliable single-source partner throughout the product lifecycle.

As of June 30, 2025, WuXi Biologics is actively managing a portfolio of 864 integrated projects, marking one of the most extensive collections of complex biologics in the industry. This portfolio features an impressive variety, including 326 monoclonal antibodies (mAbs), 168 bispecific and multispecific antibodies, 225 antibody-drug conjugates (ADCs), 80 fusion proteins, and 25 vaccines. Remarkably, the development timeframe for mAbs has been slashed to just nine months from DNA to Investigational New Drug (IND) application, while certain projects, including those for autoimmune diseases, have been successfully completed in just six months.

The organization employs single-use technology (SUT) in tandem with a scale-out strategy, resulting in the production of over 300 batches across scales ranging from 4,000 to 16,000 liters at its global facilities. This method has led to an impressive success rate of 98% since 2022. Notably, the costs associated with SUT manufacturing are now on par with those of traditional stainless-steel systems, providing both efficiency and savings.

Regulatory Excellence

Supporting these milestones is WuXi Biologics' commitment to maintaining world-class quality systems. The company has achieved a flawless 100% success rate in Pre-License Inspections (PLI) and has successfully passed 44 inspections by regulatory agencies across the globe, including 22 inspections conducted by the U.S. FDA and European Medicines Agency (EMA).

A Leader in Change

In a statement, Unmesh Lal, Vice President of Healthcare & Life Sciences at Frost & Sullivan, noted, “In today's fast-changing biopharmaceutical industry, marked by increasing healthcare demands and geopolitical complexities, WuXi Biologics is at the forefront of transforming the CRDMO model. By globalizing its operations, strengthening supply chain resilience, and catalyzing innovation through an integrated platform, WuXi Biologics empowers its clients to navigate uncertainties while facilitating faster and more flexible biologics market entry.”

Dr. Chris Chen, the CEO of WuXi Biologics, expressed gratitude for the recognition, stating, “We are honored to receive Frost & Sullivan's 2025 Global Customer Value Leadership Award. This acknowledgment is a testament to our steadfast dedication to driving biologics innovation through strategic partnerships. Our focus on generating lasting value and proactively addressing future industry requirements reinforces WuXi Biologics as the preferred ally for biopharmaceutical endeavors worldwide.”

About WuXi Biologics

Founded with a mission to revolutionize the biologics development process, WuXi Biologics is known for its comprehensive and cost-effective solutions that encompass every stage from discovery through to commercialization, ultimately benefitting patients globally. The company boasts a talented workforce of over 12,000 employees across key locations including China, the US, Ireland, Germany, and Singapore.

In addition to its operational advancements, WuXi Biologics prioritizes sustainability as a cornerstone for long-term business development. The organization actively fosters innovations in green technology to deliver advanced CRDMO solutions while consistently achieving excellence in Environment, Social, and Governance (ESG) performance. By collaborating with various stakeholders, WuXi Biologics aims to generate positive social and environmental impacts while promoting responsible practices across the value chain.

For more information about their initiatives and offerings, visit WuXi Biologics.